CD3 directed bispecific antibodies induce increased lymphocyte–endothelial cell interactions in vitro

Bispecific antibody (BsMAb) BIS-1 has been developed to redirect the cytolytic activity of cytotoxic T lymphocytes (CTL) to epithelial glycoprotein-2 (EGP-2) expressing tumour cells. Intravenous administration of BIS-1 F(ab′)(2)to carcinoma patients in a phase I/II clinical trial, caused immunomodul...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Molema, G, Tervaert, J W Cohen, Kroesen, B J, Helfrich, W, Meijer, D K F, Leij, L F M H de
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2000
Sujets:
Regular Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2363284/
https://ncbi.nlm.nih.gov/pubmed/10646907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1054/bjoc.1999.0945
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires